Argüelles-Arias, FGuerra Veloz, M FPerea Amarillo, RVilches-Arenas, ACastro Laria, LMaldonado Pérez, BChaaro, DBenítez Roldán, AMerino, VRamírez, GCaunedo Álvarez, ARomero Gómez, M2023-01-252023-01-252017-03-09http://hdl.handle.net/10668/10954CT-P13 is a biosimilar of Remicade®, an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD. To assess the effectiveness and safety of CT-P13 in IBD patients in real clinical practice. This is a prospective observational study in patients with moderate to severe Crohn's disease or ulcerative colitis treated with CT-P13. The study was performed in one single center. Patients included were naive or switched to anti-TNF treatment from the reference infliximab (Remicade®) to CT-P13. Efficacy and safety were assessed in naive and switched patients who were in remission at the time of the switch at months 3 and 6 of therapy. 87.5 and 83.9% of switched CD patients who were in remission at the time of the switch continued in remission, and 66.7 and 50% of naive CD patients reached remission, at months 3 and 6. In UC switched cases, 92 and 91.3% of patients in remission at the time of the switch continued in remission, at 3 and 6 months. In naive UC patients, the remission rates were 44.4 and 66.7%, at months 3 and 6. Adverse events occurred in 7.5% of patients during 6 months of study. CT-P13 was efficacious and well tolerated in patients with CD or UC.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/Biosimilar agentCT-P13Crohn’s diseaseInfliximabUlcerative colitisAdultAntibodies, MonoclonalDrug Administration ScheduleFemaleHumansInflammatory Bowel DiseasesMaleMiddle AgedProspective StudiesRemission Inductionresearch article28281165open access10.1007/s10620-017-4511-41573-2568PMC5487700https://link.springer.com/content/pdf/10.1007%2Fs10620-017-4511-4.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487700/pdf